DJIA 17,814.94 -2.96 -0.02%
NASDAQ 4,758.25 3.36 0.07%
S&P 500 2,067.03 -2.38 -0.12%
market minute promo

14.71 0.43 (3.01%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

INFI $14.71 3.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.44
Previous Close $14.28
Daily Range $14.15 - $14.72
52-Week Range $8.40 - $18.35
Market Cap $717.4M
P/E Ratio -64.91
Dividend (Yield) $0.00 (0.0%)
Volume 727,479
Average Daily Volume 605,987
Current FY EPS -$0.50

Sector

Healthcare

Industry

Drugs

Infinity Pharmaceuticals, Inc. (INFI) Description

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions. Website: http://www.infi.com/

News & Commentary Rss Feed

Dividend Aristocrats: Time to Buy AbbVie Inc Stock?

AbbVie is an innovative pharma company with an attractive yield and a strong outlook for top-line growth going forward. Here's why investors should dig into this top dividend stock.

Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today

Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2014 Results - Earnings Call Transcript

Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Mee

Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting

Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog

Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? - Analyst Blog

3 Health Care Picks To Beat Earnings - Earnings ESP

Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog

Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Al

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

See More INFI News...

INFI's Top Competitors

INFI $14.71 (3.01%)
Current stock: INFI
AMGN $162.24 (-1.18%)
Current stock: AMGN
GILD $101.11 (0.51%)
Current stock: GILD
BIIB $305.40 (-0.44%)
Current stock: BIIB